Studies for MM
| | | | | |
Bouko et al. [26]
|
Newly diagnosed MM, responders to 3–4 cycles of induction therapy
|
G-CSF SD
|
23
|
NA
|
NA
|
| |
Pegfilgrastim 12 mg
|
22
|
NA
|
NA
|
| |
Pegfilgrastim 18 mg
|
22
|
NA
|
NA
|
Czerw et al. [30]
|
MM patients, age 18–65 years, CR or PR achieved after at least one line of therapy
|
G-CSF SD
|
46
|
60 (37–65)
|
57%
|
| |
ID-AraC + G-CSF SD
|
44
|
56 (33–65)
|
61%
|
DiPersio et al. [33]
|
Diagnosis of MM, age 18–78 years, in first or second CR or PR
|
G-CSF SD
|
154
|
58.4 ± 8.6
|
68%
|
| |
G-CSF SD + Plerixafor SD
|
148
|
58.2 ± 8.4
|
70%
|
Nahi et al. [50]
|
Diagnosis of MM, age ≥ 18 years, in CR or PR
|
G-CSF SD
|
10
|
58 (42–69)
|
60%
|
| |
G-CSF SD + Plerixafor SD
|
10
|
59 (43–70)
|
40%
|
Ri et al. [55]
|
Diagnosis of MM, age 20–75 years, in first or second CR or PR
|
G-CSF SD
|
7
|
60 (49–67)
|
57%
|
| |
G-CSF SD + Plerixafor SD
|
7
|
60 (38–71)
|
57%
|
Silvennoinen et al. [58]
|
Transplant-eligible MM patients aged ≤ 70 years
|
G-CSF SD
|
35
|
63 (40–70)
|
54%
|
| |
CY + G-CSF RD
|
34
|
62 (48–69)
|
53%
|
Skopec et al. [59]
|
Newly diagnosed MM treated with 3–6 cycles of Bor and Dex
|
G-CSF SD
|
20
|
60 (35–69)
|
55%
|
| |
Pegfilgrastim 12 mg
|
19
|
64 (51–71)
|
47%
|
Valtola et al. [61]
|
Transplant-eligible MM patients less than 70 years of age
|
G-CSF SD
|
19
|
63 (52–70)
|
42%
|
| |
CY + G-CSF RD
|
17
|
58 (49–70)
|
59%
|
Studies for NHL
| | | | | |
DiPersio et al. [32]
|
Diagnosis of NHL, age 18–78 years, in first or second CR or PR
|
G-CSF SD
|
148
|
59 (22–75)
|
69%
|
| |
G-CSF SD + Plerixafor SD
|
150
|
56 (29–75)
|
67%
|
Kuruvilla et al. [43]
|
Diagnosis of NHL, age 18–78 years, in first or second CR or PR
|
G-CSF SD + Plerixafor SD
|
31
|
47.8 ± 13.6
|
55%
|
| |
G-CSF SD + Plerixafor FD
|
30
|
46.1 ± 13.4
|
60%
|
Liu et al. [44]
|
NHL patients, age 18–65 years, achieving CR or PR after first- or second-line therapy
|
G-CSF SD
|
50
|
50 (18–64)
|
50%
|
| |
G-CSF SD + YF-H-2015005
|
51
|
45 (18–65)
|
53%
|
Matsue et al. [48]
|
Diagnosis of NHL, age 20–75 years, in first CR or PR
|
G-CSF SD
|
16
|
63 (27–70)
|
75%
|
| |
G-CSF SD + Plerixafor SD
|
16
|
56 (39–73)
|
69%
|
Zhu et al. [66]
|
Diagnosis of NHL, age 18–75 years, in first or second CR or PR
|
G-CSF SD
|
50
|
43 (20–60)
|
52%
|
| |
G-CSF SD + Plerixafor SD
|
50
|
39 (18–66)
|
62%
|